# US 10,864,216 B2 · Phenothiazine diaminium salts and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,216 B2
- Document ID: US10864216B2
- Status: Granted
- Kind: B2
- Application number: 15/912,166
- Filed: 2018-03-05
- Published: 2019-02-14
- Granted: 2020-12-15
- Earliest claimed: 2011-02-11
- Assignees: WisTa Laboratories Ltd.
- Applicants: WisTa Laboratories Ltd.
- Inventors: Colin Marshall; Scott Clunas; John Mervyn David Storey; James Peter Sinclair; Thomas Craven Baddeley; Ahtsham Ishaq; Michael Simpson; Craig Williamson; Barry Alan Wood; Claude Michel Wischik; Charles Robert Harrington; Janet Elizabeth Rickard; David Horsley; Yin Sze Loh; Karrar Ahmad Khan; Christopher Paul Larch
- Web page: https://patentgrep.com/patent/US10864216B2

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2095: {Tabletting processes}
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 279/20: with hydrogen atoms directly attached to the ring nitrogen atom
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61L 2/084: Visible light
- A61L 2103/05: Living organisms or biological materials
- C07C 303/32: of salts of sulfonic acids
- C07C 309/04: containing only one sulfo group
- C07C 309/05: containing at least two sulfo groups bound to the carbon skeleton
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- C07C 309/35: Naphthalene sulfonic acids
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

## Claims

### Claim 1

A method of treating a disease selected from the group consisting of: skin cancer or melanoma; a viral disease; a bacterial disease; and a protozoal disease, the method comprising administering to a subject in need thereof the compound of the following formula:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering is oral.

### Claim 3 (depends on 2)

The method of claim 2, wherein the administering is selected from:
(a) about 100 mg of compound, 3 times daily;
(b) about 150 mg of compound, 2 times daily; and
(c) about 200 mg of compound, 2 times daily.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disease is skin cancer or melanoma.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease is a viral disease.

### Claim 6 (depends on 5)

The method of claim 5, wherein the viral disease is selected from the list consisting of: Hepatitis C; HIV; and West Nile Virus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease is a bacterial disease.

### Claim 8 (depends on 1)

The method of claim 1, wherein the disease is a protozoal disease.

### Claim 9 (depends on 7)

The method of claim 7, wherein the protozoal disease is malaria.